口服蛋白質和多肽市場 - 全球行業規模、佔有率、趨勢、機會和預測，按藥物類型、應用、地區和競爭細分，2020-2030 年預測

2024 年全球口服蛋白質和胜肽市場價值為 13.3 億美元，預計在預測期內將經歷顯著成長，到 2030 年的年複合成長率(CAGR) 為 9.42%。該市場正在製藥和生物技術領域迅速擴張。口服蛋白質和胜肽是可以口服的生物活性分子，通常為片劑、膠囊或液體形式，為注射療法提供了替代方案。這種給藥方法有多種優點，包括提高病患的依從性、減少不適感、降低醫療成本。

主要市場促進因素：

慢性病盛行率不斷上升

主要市場挑戰：

穩定性和生物利用度

主要市場趨勢：

奈米技術和藥物傳輸系統的進展

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球口服蛋白質與胜肽市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依藥物類型（降鈣素、胰島素、利那洛肽、奧曲肽、普卡那肽）
  • 依應用（骨骼病變、糖尿病、胃及消化系統疾病、荷爾蒙失調）
  • 按地區
  • 按公司分類（2024）
• 產品市場圖
  • 依藥物類型
  • 按應用
  • 按地區

第 6 章：北美口服蛋白質和多胜肽市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲口服蛋白質和多胜肽市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 法國
  • 義大利
  • 西班牙

第 8 章：亞太口服蛋白質和多胜肽市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 日本
  • 印度
  • 澳洲
  • 韓國

第 9 章：南美洲口服蛋白質和多胜肽市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲口服蛋白質和多胜肽市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 科威特

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 合併與收購
• 產品發布

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• AbbVie Inc.
• Merck & Co Inc
• Pfizer Inc
• Novo Nordisk A/S
• Hoffmann-La Roche Inc
• Sanofi SA
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Tarsa Therapeutics Inc
• Novartis AG

第 15 章：策略建議

第16章調查會社について,免責事項

The Global Oral Proteins & Peptides Market was valued at USD 1.33 billion in 2024 and is expected to experience significant growth during the forecast period, with a compound annual growth rate (CAGR) of 9.42% through 2030. This market is rapidly expanding within the pharmaceutical and biotechnology sectors. Oral proteins and peptides are bioactive molecules that can be taken orally, typically in the form of tablets, capsules, or liquids, providing an alternative to injectable therapies. This method of administration offers multiple advantages, including improved patient compliance, reduced discomfort, and lower healthcare costs.

Key Market Drivers:

Increasing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a key factor driving the growth of the oral proteins and peptides market. As the global population ages and lifestyles become more sedentary and unhealthy, the incidence of chronic diseases is increasing. This leads to a larger patient pool that could benefit from oral protein and peptide treatments. According to the World Health Organization, noncommunicable diseases (NCDs) were responsible for 43 million deaths, accounting for 75% of all global deaths unrelated to pandemics. Cardiovascular diseases were the leading cause with 19 million deaths, followed by cancers (10 million), chronic respiratory diseases (4 million), and diabetes (over 2 million). Notably, low- and middle-income countries accounted for 73% of these NCD-related deaths.

Patients with chronic conditions are increasingly seeking convenient treatment options. Many require long-term or lifelong therapies, and traditional methods such as injections or infusions can be burdensome. Oral proteins and peptides provide a more patient-friendly alternative, as they can be taken in the form of a pill or liquid, eliminating the need for painful, frequent injections. Additionally, non-adherence to prescribed treatments is a significant challenge in managing chronic diseases. Oral formulations help address this issue by increasing patient compliance, as treatments that are easier to administer and less intrusive encourage better adherence and lead to improved health outcomes.

Key Market Challenges:

Stability and Bioavailability

A major challenge in the oral administration of proteins and peptides is their susceptibility to degradation in the harsh environment of the gastrointestinal tract. Ensuring their stability and maintaining adequate bioavailability remains a complex issue that requires advanced formulation technologies.

Key Market Trends:

Advancements in Nanotechnology and Drug Delivery Systems

Nanotechnology is transforming drug delivery in the oral proteins and peptides market. Nanoparticles and nanocarriers are being developed to encapsulate and protect these sensitive molecules, enabling more precise delivery and enhanced bioavailability. These innovations are expected to expand the range of treatable diseases and improve therapeutic outcomes.

Key Market Players:

• AbbVie Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Novo Nordisk A/S
• Hoffmann-La Roche Inc.
• Sanofi S.A.
• AstraZeneca PLC
• Bristol-Myers Squibb Co.
• Tarsa Therapeutics Inc.
• Novartis AG

Report Scope:

This report segments the Global Oral Proteins & Peptides Market into the following categories, with detailed insights into each:

By Drug Type:

• Calcitonin
• Insulin
• Linaclotide
• Octreotide
• Plecanatide

By Application:

• Bone Diseases
• Diabetes
• Gastric & Digestive Disorders
• Hormonal Disorders

By Region:

• North America: United States, Canada, Mexico
• Europe: Germany, United Kingdom, France, Italy, Spain
• Asia-Pacific: China, Japan, India, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE, Kuwait

Competitive Landscape and Company Profiles:

This section offers an in-depth analysis of the major players in the Global Oral Proteins & Peptides Market.

Available Customizations:

TechSci Research provides customized reports tailored to specific market needs. The following customization options are available:

• Detailed analysis and profiling of up to five additional market players.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Proteins & Peptides Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 5.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Drug Type
  • 5.3.2. By Application
  • 5.3.3. By Region

6. North America Oral Proteins & Peptides Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 6.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oral Proteins & Peptides Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Oral Proteins & Peptides Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Oral Proteins & Peptides Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application

7. Europe Oral Proteins & Peptides Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 7.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oral Proteins & Peptides Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Oral Proteins & Peptides Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
  • 7.3.3. France Oral Proteins & Peptides Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Oral Proteins & Peptides Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Oral Proteins & Peptides Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Oral Proteins & Peptides Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 8.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Oral Proteins & Peptides Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Japan Oral Proteins & Peptides Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
  • 8.3.3. India Oral Proteins & Peptides Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
  • 8.3.4. Australia Oral Proteins & Peptides Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
  • 8.3.5. South Korea Oral Proteins & Peptides Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application

9. South America Oral Proteins & Peptides Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 9.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Oral Proteins & Peptides Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Oral Proteins & Peptides Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Oral Proteins & Peptides Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Oral Proteins & Peptides Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 10.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Oral Proteins & Peptides Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Oral Proteins & Peptides Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Oral Proteins & Peptides Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
  • 10.3.4. Kuwait Oral Proteins & Peptides Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Type
      • 10.3.4.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. AbbVie Inc.
• 14.2. Merck & Co Inc
• 14.3. Pfizer Inc
• 14.4. Novo Nordisk A/S
• 14.5. Hoffmann-La Roche Inc
• 14.6. Sanofi SA
• 14.7. AstraZeneca PLC
• 14.8. Bristol-Myers Squibb Co
• 14.9. Tarsa Therapeutics Inc
• 14.10.Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer